PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

Structure Therapeutics CEO Ray Stevens outlined the company's strategy to compete in the crowded weight-loss drug market at the JPMorgan Healthcare Conference. The company plans to advance its daily oral GLP-1 candidate, aleniglipron, into Phase 3 trials. Phase 2 data showed 11% body weight loss at 36 weeks (adjusted for placebo), with higher doses achieving up to 15.3% loss. Stevens highlighted four competitive advantages: efficacy, absence of drug-related liver injuries, cost-effective manufacturing as a small-molecule pill, and potential for combination therapy. He also warned about the risks posed by unapproved alternatives in the market.

FMR LLC, a Johnson family-controlled company and 10% owner of Structure Therapeutics, sold 52,356 shares worth approximately $3.8 million on December 8, 2025. Despite this insider sale, the clinical-stage biopharmaceutical company's stock has surged 212.55% over the past year, with continued momentum in 2026. The company recently closed a $748 million public offering and is developing a competitive weight loss pill.

Structure Therapeutics has priced a public offering of 8,461,538 American depositary shares at $65.00 per share and pre-funded warrants to purchase 1,538,462 ADSs, expecting to raise approximately $650 million.

Structure Therapeutics plans to release topline data from its ACCESS clinical program for aleniglipron, an oral small molecule GLP-1 receptor agonist for obesity treatment, on December 8, 2025.

Structure Therapeutics is developing an oral weight-management drug called aleniglipron, targeting the hot obesity treatment market. The company's success depends on strong clinical trial results, with potential for significant stock price movement based on its phase 2 study outcomes.

Eli Lilly's oral GLP-1 drug orforglipron underperformed in weight loss trials, potentially creating opportunities for competitors like Novo Nordisk in the emerging oral weight management medication market.

Structure Therapeutics, a clinical-stage biopharmaceutical company, announced two late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions. The presentations will include preclinical data for their oral small molecule amylin agonist, ACCG-2671, and their oral small molecule GLP-1 receptor agonist, GSBR-5595.

Pfizer announced it will discontinue development of its oral GLP-1 weight loss pill danuglipron due to the risk of liver injury. This news benefits Eli Lilly, Novo Nordisk, and Viking Therapeutics, who are now in a better position in the GLP-1 weight loss drug market.

Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.

Pfizer's challenging period may be turning around with strong Q1 performance and potential changes under new leadership. Learn more about PFE stock's buy rating.

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.